COMPLETED

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

Talk to us

Conditions

Chronic Weight Management

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.

Official Title

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity or Overweight With Weight-Related Comorbidities

Quick Facts

Study Start:2025-07-03
Study Completion:2025-12-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT07002905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Have provided informed consent before initiation of any study-specific procedures.
  2. * Male or female participants, non-smokers, between 18 and 75 years of age (both inclusive).
  3. * No clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and other screening procedures.
  1. * Have evidence of any clinically significant active or chronic disease.
  2. * Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or rare forms of diabetes mellitus.
  3. * Have an autoimmune disease, is immunosuppressed or is in any way immunocompromised.
  4. * Have a history of acute or chronic pancreatitis.
  5. * Participants with a known clinically significant gastric emptying abnormality.
  6. * Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy.
  7. * Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the Investigator, may preclude the participant from following and completing the protocol.

Contacts and Locations

Study Locations (Sites)

Ascletis Clinical Site
Rogers, Arkansas, 72758
United States
Ascletis Clinical Site
Fort Myers, Florida, 33912
United States
Ascletis Clinical Site
Miami, Florida, 33172
United States
Ascletis Clinical Site
Columbus, Ohio, 43212
United States
Ascletis Clinical Site
Bellaire, Texas, 77401
United States
Ascletis Clinical Site
San Antonio, Texas, 78240
United States

Collaborators and Investigators

Sponsor: Ascletis Pharma (China) Co., Limited

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-03
Study Completion Date2025-12-08

Study Record Updates

Study Start Date2025-07-03
Study Completion Date2025-12-08

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Weight Management